Antisense Therapeutics


Market CapAU$58m

Last Close AU$0.09

Antisense Therapeutics is an Australia-based biopharmaceutical company developing and commercialising Antisense pharmaceuticals for rare diseases. The company’s lead clinical asset is ATL1102, an ASO therapy being investigated for the treatment of DMD.

More Antisense Therapeutics content >

Investment summary

Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide (ASO) therapies for the treatment of rare diseases. Its lead asset, ATL1102, is being investigated as a targeted anti-inflammatory therapy to treat Duchenne muscular dystrophy (DMD). In a positive strategic pivot, trial design was amended to a smaller Phase IIb study (n=42 vs 108) that should provide a nearer-term catalyst, if positive readouts are achieved. As a result of the reduced trial costs, the company’s cash runway is anticipated to be extended (net cash at end-June 2022 of A$19.2m) into Q4 CY23. Management envisages a need to raise funds in the mid-single digit (A$m) region, which it anticipates will fund operations to trial readouts in Q124.

Content on Antisense Therapeutics
Antisense Therapeutics – Breaking the mould in DMD treatment
Healthcare | research QuickView | 11 October 2022
Motor neuron connecting to muscle fiber, 3D illustration
View more
Share price graph
Price performance
Actual 7.5 (5.5) (58.0)
Relative* 1.4 (8.7) (57.5)
52-week high/low A$0.2/A$0.1
*% relative to local index